Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The March 2016 monograph topics are necitumumab, talimogene laherparepvec, asfotase alfa, trabectedin, and osimertinib. The Safety MUE is on patiromer.
JacqueminM.ToelenJ.SchoetersJ.The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders. J Thromb Haemost.2015; 13(11): 2087–2092.
4.
SchieleF.van RynJ.CanadaK.A specific antidote for dabigatran: Functional and structural characterization. Blood.2013; 121(18): 3554–3562.
5.
GrottkeO.van RynJ.SpronkH.M.RossaintR.Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care.2014; 18(1): R27.
6.
GlundS.MoschettiV.NorrisS.A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost.2015; 113(5): 943–951.
7.
PollackC.V.JrReillyP.A.EikelboomJ.Idarucizumab for dabigatran reversal. N Engl J Med.2015; 373(6): 511–520.
8.
PollackC.V.JrReillyP.A.BernsteinR.Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost.2015; 114(1): 198–205.
9.
GrottkeO.HonickelM.van RynJ.Ten CateH.RossaintR.SpronkH.A specific antidote (idarucizumab) to dabigatran reduces blood loss and improves coagulopathy in a dabigatran- and trauma-induced bleeding model in pigs [abstract 6AP3-2]. Eur J Anaesthesiol.2014; 31(suppl 52): 95–96.
10.
HonickelM.BraunschweigT.van RynT.RossaintR.GrottkeO.Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model [abstract]. Crit Care.2015; 19(suppl 1): abstract P351.
11.
GlundS.StangierJ.SchmohlM.Idarucizumab, a specific antidote for dabigatran: Immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects [abstract]. Blood.2014; 124(21): abstract 344.
12.
HonickelM.TreutlerS.van RynJ.TillmannS.RossaintR.GrottkeO.Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost.2015; 113(4): 728–740.
13.
GrottkeO.HonickelM.van RynJ.Ten CateH.SpronkH.RossaintR.Dabigatran-induced anticoagulant and bleeding effects can be reversed with both prothrombin complex concentrates and a specific antidote (idarucizumab) in a lethal porcine polytrauma model [abstract 4844]. Eur Heart J.2014; 35: s863.
14.
GrottkeO.HonickelM.SchurerJ.van RynJ.Reversal of trauma-induced bleeding and anticoagulation with a dabigatran-specific antidote (idarucizumab) as assessed by shed and washed blood tests in a pig model of supratherapeutic anticoagulation and trauma [abstract]. Blood.2014; 124(21): abstract 4268.
15.
GrottkeO.HonickelM.van RynJ.Ten CateH.RossaintR.SpronkH.M.Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol.2015; 66(13): 1518–1519.
16.
HonickelM.GrottkeO.van RynJ.Ten CateH.RossaintR.SpronkH.Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs [abstract]. Crit Care.2014; 18(suppl 1): abstract P99.
17.
VeltkampR.MracskoE.van RynJ.NaS.Y.Idarucizumab, a specific antidote to dabigatran, prevents hematoma enlargement and reduces mortality in experimental intracerebral hemorrhage in mice [abstract LB P4]. International Stroke Conference 2015; February 11–13, 2015; Nashville, TN. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_471774.pdf. Published February 11, 2015. Accessed April 30, 2015.
18.
NaS.Y.MracskoE.van RynJ.VeltkampR.Idarucizumab improves outcome in murine brain hemorrhage related to dabigatran. Ann Neurol.2015; 78(1): 137–141.
19.
KaatzS.KouidesP.A.GarciaD.A.Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors [published correction appears in Am J Hematol. 2012;87(7): 748]. Am J Hematol.2012; 87(suppl 1): s141–145.
20.
MakrisM.Van VeenJ.J.TaitC.R.MumfordA.D.LaffanM; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol.2013; 160(1): 35–46.
GrottkeO.ZentaiC.van RynJ.Ten CateH.RossaintR.SpronkH.Binding of dabigatran to its specific antidote, idarucizumab, is not influenced by infusion solutions used during resuscitation in a porcine hemorrhagic shock model [abstract 6AP3-6]. Eur J Anaesthesiol.2014; 31(suppl 52): 97.
23.
GlundS.StangierJ.SchmohlM.Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: A randomised, placebo-controled, double-blind phase 1 trial. Lancet.2015; 386(9994): 680–690.
24.
van RynJ.SchmollM.PilluH.Effect of dabigatran on the ability to generate fibrin at a wound site and its reversal by idarucizumab, the antidote to dabigatran, in healthy volunteers: An exploratory marker of blood loss [abstract].Circulation. 2014;130: A18403. http://circ.ahajournals.org/content/130/Suppl_2/A18403.short. Accessed April 29, 2015.
